Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 8, 2026

Direct Induction of Human Neural Stem Cells from Peripheral Blood Hematopoietic Progenitor Cells
12:06

Direct Induction of Human Neural Stem Cells from Peripheral Blood Hematopoietic Progenitor Cells

Published on: January 28, 2015

Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early

S Sinha1, D Gastineau, I Micallef

  • 1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Bone Marrow Transplantation
|October 12, 2010
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Surface-Topography Challenge: A Multi-Laboratory Benchmark Study to Advance the Characterization of Topography.

Tribology letters·2025
Same author

Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement.

Leukemia & lymphoma·2024
Same author

Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.

Leukemia·2024
Same author

iMPI: portable human-sized magnetic particle imaging scanner for real-time endovascular interventions.

Scientific reports·2023
Same author

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.

Blood cancer journal·2023
Same author

Estimating risk probabilities for sickness from behavioural patterns to identify health challenges in dairy cows with multivariate cumulative sum control charts.

Animal : an international journal of animal bioscience·2022
Same journal

CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Bone marrow transplantation·2026
Same journal

Transplant outcomes for patients with severe acquired aplastic anemia over the age of 40 using busulfan, fludarabine, reduced-dose cyclophosphamide, and anti-thymocyte globulin conditioning regimen.

Bone marrow transplantation·2026
Same journal

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same journal

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026
Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
See all related articles
This summary is machine-generated.

Predicting poor peripheral blood stem cell (PBSC) collection using CD34 counts can prevent costly remobilization. This study identifies specific CD34 thresholds for multiple myeloma and lymphoma patients to ensure successful PBSC collection.

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Oncology

Background:

  • Peripheral Blood Stem Cell (PBSC) mobilization commonly uses G-CSF, with or without chemotherapy.
  • Predicting mobilization failure is crucial for timely intervention and avoiding remobilization complications.
  • Emerging mobilizing agents necessitate refined prediction strategies for successful PBSC collection.

Purpose of the Study:

  • To identify optimal peripheral blood CD34 count (PB-CD34) thresholds for predicting successful PBSC collection in patients with plasma cell disorders and lymphomas.
  • To establish PB-CD34 cutoffs that enable early intervention and prevent collection failures.
  • To correlate PB-CD34 counts and yields with target collection goals for different hematologic malignancies.

Main Methods:

More Related Videos

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

Related Experiment Videos

Last Updated: Jun 8, 2026

Direct Induction of Human Neural Stem Cells from Peripheral Blood Hematopoietic Progenitor Cells
12:06

Direct Induction of Human Neural Stem Cells from Peripheral Blood Hematopoietic Progenitor Cells

Published on: January 28, 2015

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

  • Retrospective analysis of 1556 patients with multiple myeloma, non-Hodgkin's lymphoma (NHL), amyloidosis, or Hodgkin's disease.
  • Evaluation of patients mobilized with single-agent G-CSF between January 2000 and September 2008.
  • Sensitivity and specificity analysis to determine ideal PB-CD34 count cutoffs for predicting successful PBSC collection.

    • Main Results:

    • For plasma cell disorders, PB-CD34 counts of 11, 17, 21, and 28/microL by day 4-5 predicted collection of 2, 4, 8, and 12 million cells/kg, respectively.
    • A CD34 yield <0.8 million cells/kg on first apheresis predicted <2 million CD34 cells/kg.
    • In NHL/Hodgkin's disease, PB-CD34 <6/microL (day 4-5) predicted failure to collect 2 million cells/kg, and <15/microL predicted failure to collect 4 million cells/kg.

    Conclusions:

    • PB-CD34 thresholds should be tailored to specific collection targets for different hematologic malignancies.
    • Establishing these thresholds allows for early identification of patients at risk for poor mobilization.
    • This approach can optimize resource utilization and improve patient outcomes by preventing remobilization attempts.